HC Wainwright Reaffirms Buy Rating for Zentalis Pharmaceuticals (NASDAQ:ZNTL)

HC Wainwright reissued their buy rating on shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL) in a research report report published on Friday morning,Benzinga reports. HC Wainwright currently has a $20.00 target price on the stock. HC Wainwright also issued estimates for Zentalis Pharmaceuticals’ Q3 2025 earnings at ($0.67) EPS and Q4 2025 earnings at ($0.68) EPS.

A number of other brokerages have also weighed in on ZNTL. Oppenheimer restated an “outperform” rating and issued a $20.00 price objective on shares of Zentalis Pharmaceuticals in a report on Monday, September 16th. Wedbush upgraded Zentalis Pharmaceuticals from an “underperform” rating to a “neutral” rating and set a $4.00 price target for the company in a research note on Monday, August 12th. Five research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $10.00.

Zentalis Pharmaceuticals Stock Performance

Zentalis Pharmaceuticals stock traded down $0.48 during mid-day trading on Friday, reaching $3.47. The stock had a trading volume of 1,832,087 shares, compared to its average volume of 1,566,191. The company has a 50-day moving average price of $3.42 and a two-hundred day moving average price of $5.46. Zentalis Pharmaceuticals has a one year low of $2.66 and a one year high of $18.07.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in ZNTL. Decheng Capital LLC grew its stake in shares of Zentalis Pharmaceuticals by 46.2% during the 2nd quarter. Decheng Capital LLC now owns 3,070,442 shares of the company’s stock valued at $12,558,000 after acquiring an additional 970,859 shares during the period. Verition Fund Management LLC increased its holdings in Zentalis Pharmaceuticals by 172.1% in the 3rd quarter. Verition Fund Management LLC now owns 1,504,320 shares of the company’s stock valued at $5,536,000 after acquiring an additional 951,500 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its position in shares of Zentalis Pharmaceuticals by 20.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,489,709 shares of the company’s stock worth $54,999,000 after buying an additional 585,644 shares in the last quarter. Renaissance Technologies LLC raised its holdings in shares of Zentalis Pharmaceuticals by 152.6% during the 2nd quarter. Renaissance Technologies LLC now owns 661,682 shares of the company’s stock worth $2,706,000 after acquiring an additional 399,745 shares in the last quarter. Finally, GSA Capital Partners LLP raised its stake in Zentalis Pharmaceuticals by 138.5% during the third quarter. GSA Capital Partners LLP now owns 608,585 shares of the company’s stock valued at $2,240,000 after purchasing an additional 353,384 shares in the last quarter.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.